111 related articles for article (PubMed ID: 30297390)
1. Prostate cancer aggressiveness and age: Impact of p53, BCL-2 and microvessel density.
Calvocoressi L; Uchio E; Ko J; Radhakrishnan K; Aslan M; Concato J
J Investig Med; 2018 Dec; 66(8):1142-1146. PubMed ID: 30297390
[TBL] [Abstract][Full Text] [Related]
2. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Factors of Prostate Cancer in Tunisian Men: Immunohistochemical Study.
Missaoui N; Abdelkarim SB; Mokni M; Hmissa S
Asian Pac J Cancer Prev; 2016; 17(5):2655. PubMed ID: 27268646
[TBL] [Abstract][Full Text] [Related]
4. Molecular markers and death from prostate cancer.
Concato J; Jain D; Uchio E; Risch H; Li WW; Wells CK
Ann Intern Med; 2009 May; 150(9):595-603. PubMed ID: 19414838
[TBL] [Abstract][Full Text] [Related]
5. Relationship between apoptosis regulator proteins (bcl-2 and p53) and Gleason score in prostate cancer.
Karaburun Paker S; Kilicarslan B; Ciftcioglu AM; Oztekin S; Sargin FC; Erdogru T; Baykara M
Pathol Oncol Res; 2001; 7(3):209-12. PubMed ID: 11692148
[TBL] [Abstract][Full Text] [Related]
6. p53, Bcl-2 and AgNOR tissue markers: model approach in predicting prostate cancer characteristics.
Munda M; Hajdinjak T; Kavalar R; Stiblar Martincic D
J Int Med Res; 2009; 37(6):1868-76. PubMed ID: 20146885
[TBL] [Abstract][Full Text] [Related]
7. Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone.
Erbersdobler A; Fritz H; Schnöger S; Graefen M; Hammerer P; Huland H; Henke RP
Eur Urol; 2002 Jan; 41(1):40-6. PubMed ID: 11999464
[TBL] [Abstract][Full Text] [Related]
8. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate.
Theodorescu D; Broder SR; Boyd JC; Mills SE; Frierson HF
J Urol; 1997 Jul; 158(1):131-7. PubMed ID: 9186339
[TBL] [Abstract][Full Text] [Related]
9. Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease.
Di Lorenzo G; De Placido S; Autorino R; De Laurentiis M; Mignogna C; D'Armiento M; Tortora G; De Rosa G; D'Armiento M; De Sio M; Bianco AR; D'Armiento FP
Prostate Cancer Prostatic Dis; 2005; 8(1):54-9. PubMed ID: 15655565
[TBL] [Abstract][Full Text] [Related]
10. Thrombospondin-1 expression in patients with pathologic stage T3 prostate cancer undergoing radical prostatectomy: association with p53 alterations, tumor angiogenesis, and tumor progression.
Grossfeld GD; Carroll PR; Lindeman N; Meng M; Groshen S; Feng AC; Hawes D; Cote RJ
Urology; 2002 Jan; 59(1):97-102. PubMed ID: 11796289
[TBL] [Abstract][Full Text] [Related]
11. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.
Moul JW; Bettencourt MC; Sesterhenn IA; Mostofi FK; McLeod DG; Srivastava S; Bauer JJ
Surgery; 1996 Aug; 120(2):159-66; discussion 166-7. PubMed ID: 8751578
[TBL] [Abstract][Full Text] [Related]
12. Correlation of p53 protein accumulation and Bcl-2 overexpression with histopathological features in prostatic cancer.
Lin JT; Wang JS; Jiann BP; Yu CC; Tsai JY; Huang JK; Wu TT
J Formos Med Assoc; 2005 Nov; 104(11):864-7. PubMed ID: 16496070
[TBL] [Abstract][Full Text] [Related]
13. The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma.
Byrne RL; Horne CH; Robinson MC; Autzen P; Apakama I; Bishop RI; Neal DE; Hamdy FC
Br J Urol; 1997 Feb; 79(2):190-5. PubMed ID: 9052469
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy.
Abaza R; Diaz LK; Laskin WB; Pins MR
J Urol; 2006 Dec; 176(6 Pt 1):2701-5. PubMed ID: 17085199
[TBL] [Abstract][Full Text] [Related]
15. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting.
Borre M; Stausbol-Gron B; Overgaard J
J Urol; 2000 Sep; 164(3 Pt 1):716-21. PubMed ID: 10953132
[TBL] [Abstract][Full Text] [Related]
16. p53 and bcl-2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomy.
Oxley JD; Winkler MH; Parry K; Brewster S; Abbott C; Gillatt DA
BJU Int; 2002 Jan; 89(1):27-32. PubMed ID: 11849156
[TBL] [Abstract][Full Text] [Related]
17. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
[TBL] [Abstract][Full Text] [Related]
18. Prognostic markers in clinically localized prostate cancer.
Pettaway CA
Tech Urol; 1998 Mar; 4(1):35-42. PubMed ID: 9568775
[TBL] [Abstract][Full Text] [Related]
19. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer.
Bubendorf L; Tapia C; Gasser TC; Casella R; Grunder B; Moch H; Mihatsch MJ; Sauter G
Hum Pathol; 1998 Sep; 29(9):949-54. PubMed ID: 9744310
[TBL] [Abstract][Full Text] [Related]
20. An analysis of microvessel density, androgen receptor, p53 and HER-2/neu expression and Gleason score in prostate cancer . preliminary results and therapeutic implications.
Mydlo JH; Kral JG; Volpe M; Axotis C; Macchia RJ; Pertschuk LP
Eur Urol; 1998; 34(5):426-32. PubMed ID: 9803006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
